Enovis (NYSE: ENOV) Beats Q1 2026 Estimates, Reaffirms Full-Year Guidance

Enovis Corporation (NYSE: ENOV) shares rose $0.73 (3.03%) to $24.85 after the company reported first-quarter 2026 results that came in ahead of consensus estimates, with particularly strong performance in its Reconstructive segment. Management simultaneously reaffirmed its full-year 2026 revenue, adjusted EBITDA, adjusted EPS, and free cash flow guidance, providing additional reassurance to investors.

Q1 2026 At a Glance

• Total revenue: $589.15M, up 5% on a reported basis year-over-year (vs. $558.83M in Q1 2025)
• Adjusted EPS: $0.89, beating consensus estimates
• Reconstructive segment revenue growth: 11% on a reported basis
• Net loss: $8.8M for the quarter
• Gross margin: 60.9% | Operating margin: 6.1%
• SEC filing: Results of Operations 8-K filed May 7, 2026

What Drove the Results

The standout driver in the quarter was the Reconstructive segment, which delivered 11% reported revenue growth — well ahead of the company's overall 5% top-line expansion. This segment, focused on joint reconstruction and orthopedic implants, has been central to Enovis's strategic repositioning following its prior portfolio transformation. The segment's outperformance suggests continued procedure volume recovery and competitive traction in key product lines.

On a profitability basis, the 60.9% gross margin reflects the company's higher-value medical device mix, though the -52.7% net margin highlights the weight of below-the-line charges — consistent with a net loss of $8.8M reported in Q1. The 6.1% operating margin indicates that core operations are generating positive results, even as non-operating items pressure the bottom line.

Wall Street View

Analyst sentiment toward Enovis (NYSE: ENOV) remains firmly constructive. As of May 1, 2026, the consensus stands at 6 Strong Buy, 10 Buy, and 2 Hold ratings, with zero Sell or Strong Sell recommendations — a distribution that was unchanged from the prior period reviewed on April 1, 2026. The stability of the ratings profile through the quarter suggests analysts were not surprised by the directional outcome. With a forward P/E of 6.2x against a $1.4B market cap, the valuation remains notably compressed relative to the broader medical device peer group.

Investor Takeaway

Enovis (NYSE: ENOV) delivered a clean beat in Q1 2026, anchored by double-digit Reconstructive growth and a reaffirmation of full-year guidance across all key financial metrics. The forward P/E of 6.2x may reflect lingering investor concern over the net loss line, but the 16 Buy-or-better analyst ratings suggest the Street sees meaningful upside from current levels near $24.85 — still well below the 52-week high of $37.85. Investors will likely focus on whether Reconstructive momentum and margin progress can narrow the gap between operating performance and reported profitability in the quarters ahead.